This presentation will discuss the need for an industry-wide standard for testing the efficacy of CBD products, how this can create legitimacy and consistency throughout the industry and will explore CBD Capital Group’s results as the first company to measure CBD efficacy using the qualitative Short Form (SF)-36 Health Survey.